Industry veteran and serial entrepreneur Daphne Koller tells In Vivo about how her company, Insitro, is unleashing the potential of computational biology and machine learning to discover new drug compounds.

In this latest instalment of the In Vivo podcast Daniel Lofaso, CEO of Digital Elevator, talks about the common mistakes biotech companies make when trying to build their brand, how to connect with varied audiences and key trends the industry should keep track of in digital marketing.

Podcast: Mithra is shaking up the stagnant women’s health market with a brand new estrogenic compound. E4, or estetrol, is a natural estrogen produced by the human fetus during pregnancy, and could represent a major breakthrough in contraceptive and menopause care.

Israeli start-up 9xchange is removing some of the friction from the asset sale and acquisition process through its digital marketplace. A partnership with BenevolentAI is also helping users identify repurposing or indication expansion opportunities. In Vivo spoke with 9xchange CEO Anat Naschitz and Benevolent AI's Matthew Fujisawa.    

Infex CEO Peter Jackson discusses the state of antimicrobial resistance in the UK, and globally. He highlights the potential of a new “Netflix” style subscription model for antibiotic reimbursement, as well as future challenges for biotechs in the anti-infectives space. 

Datamonitor Healthcare analysts discuss key data presentations from the American Society of Clinical Oncology's annual meeting, which took place in Chicago, 2-6 June.

David Fajgenbaum has become a "man on fire," determined to repurpose as many generic drugs as possible for diseases without approved treatments. Fajgenbaum, whose efforts have been recognized by former President Bill Clinton, spoke with In Vivo about his own patient journey with a disease with no approved treatment and about the Every Cure Foundation, a non-profit he co-founded to fulfill his ambitions.   

In this one-off podcast, reporter Barnaby Pickering speaks Jérôme Marzinski and Dr Christian Coviello, the CEO and CTO, respectively, of OxSonics, a UK-based start-up which is working on an ultrasound-based technology that has been designed to enhance the potency of oncological drugs.